Cardiovascular Risk of Stimulant Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder: Update and Clinical Recommendations

Autor/inn/en	Hammerness, Paul G.; Perrin, James M.; Shelley-Abrahamson, Rachel; Wilens, Timothy E.
Titel	Cardiovascular Risk of Stimulant Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder: Update and Clinical Recommendations
Quelle	In: Journal of the American Academy of Child & Adolescent Psychiatry, 50 (2011) 10, S.978-990 (13 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0890-8567
DOI	10.1016/j.jaac.2011.07.018
Schlagwörter	Attention Deficit Hyperactivity Disorder; Metabolism; Stimulants; Adolescents; Patients; At Risk Persons; Heart Disorders; Correlation; Children; Drug Therapy; Identification + Suchen Sie Ihr Suchwort? Stoffwechsel; Droge; Adolescent; Adolescence; Adoleszenz; Jugend; Jugendalter; Jugendlicher; Patient; Risikogruppe; Herzkrankheit; Korrelation; Child; Kind; Kinder; Identifikation; Identifizierung
Abstract	Objective: This review provides an update on the cardiovascular impact of therapeutic stimulant-class medication for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Method: Relevant clinical literature was ascertained using PubMed searches limited to human studies and the English language as of May 2011. Current practice guidelines and consensus statements also were reviewed. Results: Stimulant-class medications for healthy children and adolescents with ADHD are associated with mean elevations in blood pressure (less than or equal to 5 mmHg) and heart rate (less than or equal to 10 beats/min) without changes in electrocardiographic parameters. A subset (5-15%) of children and adolescents treated may have a greater increase in heart rate or blood pressure at a given assessment or may report a cardiovascular-type complaint during stimulant treatment. It is extremely rare for a child or adolescent receiving stimulant medication to have a serious cardiovascular event during treatment, with the risk appearing similar to groups of children not receiving stimulant medication. Conclusions: Clinicians should adhere to current recommendations regarding the prescription of stimulant medications for youth with ADHD. Scientific inquiry is indicated to identify patients at heightened risk and to continue surveillance for the longer-term cardiovascular impact of these agents. (Contains 2 tables.) (As Provided).
Anmerkungen	Elsevier. 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Tel: 877-839-7126; Tel: 407-345-4020; Fax: 407-363-1354; e-mail: usjcs@elsevier.com; Web site: http://www.elsevier.com
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10